Backgrounds/Aims: Gas-forming pyogenic liver abscess (GFPLA) has an incidence of up to 30% of all pyogenic liver abscesses (PLA). GFPLA has higher mortality compared to non-GFPLA. Mere presence of gas within abscess may not determine clinical outcome. Hence it is important to study biologic characteristics that make GFPLA a distinct clinical entity. The aim of this study was to conduct a world review on GFPLA. Methods: We conducted literature searches in PubMed using the following MeSH terms: "gas forming" AND "Liver abscess, pyogenic", "gas" AND "Liver abscess, pyogenic", "gas" AND "Liver abscess", "gas forming" AND "Liver abscess". Thirteen case series including 313 GFPLA patients were included. Age, gender, diabetes mellitus (DM), bacteriology, underlying etiology, symptoms, investigations, operative indications, and mortality rates were tabulated. Results: GFPLA is often cryptogenic. There was no difference in age, gender, or symptomatology between GFPLA and non-GFPLA patients. DM was more common in patients with GFPLA compared to that in non-GFPLA patients (mean: 83.5% vs. 38.3%). Klebsiella pneumoniae is the most common causative pathogen. GFPLA has higher mortality compared to non-GFPLA (mean: 30.3% vs. 9%). Conclusions: GFPLA is associated with DM and monomicrobial Klebsiella pneumoniae infection. GFPLA has high mortality. It needs to be recognized as a distinct clinical entity. (Ann Hepatobiliary Pancreat Surg 2018;22:11-18)
INTRODUCTION
Pyogenic liver abscess (PLA) has an estimated annual incidence of 2.3 cases per 100,000 populations. 1 PLA can be classified by size, etiologic microorganism, and gas formation. Gas-forming PLA (GFPLA) is defined as the presence of gas within the abscess. GFPLA was first described in 1944 by Smith. 2 Scientific understanding and distinct behavior of GFPLA remain elusive. Associations of GFPLA with diabetes mellitus (DM), Klebsiella pneumoniae infection, and higher mortality have been reported. 3, 4 Due to advances in management of hepatocellular carcinoma (HCC) with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE),
GFPLA is increasingly reported. 5, 6 However, majority of studies on PLA did not report GFPLA separately. There are very few reports with distinct emphasis on GFPLA.
Heterogeneity and small sample size of reported studies restrict their clinical impact. In addition, majority of GFPLA reports are restricted to case reports of rare associations. In the era of multimodal care, the outcomes of PLA have improved and are not really determined by aetiologic microorganism 7 or size of abscess. 8 The mere presence of gas within the abscess should not be a determinant of GFPLA outcome. Hence, it is important to study biologic characteristics of GFPLA that make it a distinct clinical entity. Factors contributing to its increased mortality risk associated with gas formation should also be determined. The paucity of GFPLA reports does not permit a high quality meta-analysis or a systematic review. Hence, we performed a qualitative review to consolidate evidences and enhance our understanding of GFPLA.
MATERIALS AND METHODS
A review of English literature in PubMed was done using MeSH terms "gas forming" AND "Liver abscess, pyo- NA, not available genic", "gas" AND "Liver abscess, pyogenic", "gas" AND "Liver abscess", "gas forming" AND "Liver abscess". Furthermore, Lin et al. 15 showed that all GFPLA patients in their study had HbA1c ≥7.0%. However, these levels
were not significantly different from those in non-GFPLA patients. 15 Five authors have studied GFPLA bacteriology. 3, 4, 10, 13, 16 They all described that monomicrobial Klebsiella pneumoniae (K. pneumoniae) was the most common bacterium found in patients with GFPLA. Regarding laboratory investigations, Yang et al. 3 described that there were no significant differences in percentages of those with albumin level ≤2.5 g/dl, alkaline phosphatase ≥150 IU/L, bilirubin ≥2 mg/dl, or leukocytes ≥20,000/mm 3 between GFPLA and non-GFPLA patients. In their study, the percentage of patients who had aspartate aminotransferase (AST) level ≥100 IU/L was higher (p＜0.05) in GFPLA patients than that in non-GFPLA patients. 3 However, Chou et al. 10 described that GFPLA patients had higher levels of blood glucose 3 described GFPLA as 'diffuse hyperechoic spots with acoustic shadowing' while Chou et al. 10 described it as 'hyperechoic lesions with reverberation'. On CT scan, GFPLA was described as 'low attenuation area with
Hounsfield units similar to that of the lungs' by Yang et al. 3 whereas Chou et al. 10 described that GFPLA 'was easily diagnosed by the presence of gas'. Lee et al. 4 have studied radiographic features associated with poor prognosis. This will be discussed later in the manuscript.
Chou et al. 10 compared the singularity/multiplicity between GFPLA and non-GFPLA without finding significant difference between the two (p=0.14). predictors. 4 However, bilobar involvement, multiple abscesses, or maximal diameter of abscess was not a significant predictor of mortality. 4 Transarterial embolization/transarterial chemoembolization (TAE/TACE) is increasingly reported to be an aetiology of GFPLA. 6, 18 Chen et al. 18 reported 80% (4 out of 5 PLA cases) of TAE/TACE-related GFPLA and Huang et al. 6 reported 100% (7 out of 7) of TAE/TACE-related GFPLA.
However, the incidence of GFPLA as a complication of TAE/TACE remained low (at 0.88% 18 and 0.27%, 6 respectively).
DISCUSSION
GFPLA was described as early as 1944 by Smith. 2 It has been reported that patients with GFPLA have high mortality risk. However, there is a paucity of data on GFPLA and its distinct biologic characteristics. For the first time, an attempt to consolidate current GFPLA literature is done in a systematic manner here (Table 3) . This review has shown that GFPLA is associated with DM and Klebsiella pneumoniae infection. It presents more often with septic shock and bacteraemia. It has higher mortality. It has been reported that prompt resuscitation, parenteral antibiotics according to local antibiogram, and proactive percutaneous drainage procedures can improve outcome of PLA. 7, 8, 21 Chemaly et al. 22 have reported that blood cultures from PLA patients fail to yield a bacterial isolate in more than 60% of patients. Similarly, we have reported that pus cultures from only 60% of PLA patients yield bacteria. 22, 23 Hence, a clinician should be aware of local antibiogram and treat PLA with empirical antibiotics accordingly. In a recent international task force report from 79 countries, world's leading experts have raised awareness of healthcare workers to improve prescribing behavior in treating intra-abdominal infections and recommended that empiric antimicrobial therapy should be broad enough to cover all likely organisms because inappropriate therapy is associated with poor outcomes and the development of bacterial resistance. 24 In our previous study of 264 patients treated for culture negative PLA (CNPLA), we have found that empiric treatment according to local antibiogram is adequate, with outcomes similar to patients with Klebsiella pneumoniae PLA (KPPLA). 21 Unfortunately, due to absence of uniform reporting of bacterial isolates and rates of negative cultures, we are unable to derive conclusions for GFPLA.
The current study concludes that GFPLA is more likely due to Klebsiella pneumoniae. However, it remains unclear if this association is reflective of the overall global trend of increasing incidence of KPPLA. In earlier reports, Streptococcus milleri and Escherichia coli have been found to be common monomicrobial causative agents. 25 We have previously found that KPPLA is more likely to be associated with systemic organ dysfunction compared to CNPLA. 21 It is likely that the increased incidence of septic shock and organ dysfunction as evidenced by elevated creatinine are multifactorial in patients with GFPLA instead of being solely due to Klebsiella 26 have reported that age ＞70 years can predict mortality. Mean age of patients with GFPLA has been reported to be lower than mean age of KPPLA patients. 7 Hence, old age cannot be attributed for organ dysfunction or mortality.
In patients with KPPLA and ECPLA, the incidence of DM is approximately 40% based on our previous study. 7 The current review shows that majority (83.5%) of GFPLA patients have DM. Septic shock and organ dysfunction might be related to poor glycemic control or DM-related end-organ dysfunction. High serum glucose also impairs leukocyte function and compromises immune defense mechanisms. It is a risk for mortality. 4 However, only one study has reported that GFPLA patients have higher blood glucose levels on admission than non-GFPLA patients. 10 More data are needed to clarify the relationship between blood glucose level and GFPLA.
Our review also shows that GFPLA is associated with mono-microbial infection and raised AST levels. 4 Radiological findings such as alveolar gas pattern, pneumoperitoneum, globular configuration, shaggy margins, and total gas content can also predict mortality. 4 The retrospective nature and small sample size of published reports are limitations of our study. However, we believe that this summative review will raise awareness about GFPLA. It also provides a benchmark for future reporting. As PLA is common in Asia, understandably majority of reports are from Asia. Due to geographic diversity in overall management, there might be possible bias. However, widespread adoption and implementation of sepsis campaign guidelines with multimodal care can reduce the impact of such limitation. The higher mortality of GFPLA may be due to old reports included in the review. Hence, high volume centers need to report their experience in managing GFPLA. Furthermore, it remains to be determined if the mere presence of gas in PLA impacts outcomes or if the presence of gas is a marker of immune compromise which is a determinant of outcomes.
These conclusions can only be derived from prospective studies.
